<p>在最近的三個月裏，4 位分析師對 Orchestra BioMed Hldgs（納斯達克：OBIO）分享了他們的見解，表達了從看漲到看跌的各種觀點。</p>
<p>下表提供了他們最近評級的簡要概覽，展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師為 Orchestra BioMed Hldgs 設定了 12 個月的價格目標，顯示出平均目標為 14.5 美元，最高預估為 20.00 美元，最低預估為 11.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的 14.33 美元的平均價格目標增加了 1.19%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767992438_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767992438_0.png"/></p>
<h2>分析師評級調查：詳盡研究</h2>
<p>對金融專家如何看待 Orchestra BioMed Hldgs 的全面審查源於最近的分析師行動。以下是關鍵分析師、他們最近的評估以及評級和價格目標調整的詳細總結。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>上調</td>
<td>超配</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>宣佈</td>
<td>買入</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>維持</td>
<td>買入</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下調</td>
<td>超配</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，反映了他們對 Orchestra BioMed Hldgs 近期發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析趨勢，分析師提供定性評估，從 “跑贏大盤” 到 “跑輸大盤”。這些評級傳達了對 Orchestra BioMed Hldgs 相對於更廣泛市場的相對錶現的預期。</li>
<li><strong>價格目標：</strong> 分析師在價格目標的調整中提供了對 Orchestra BioMed Hldgs 未來價值的估計。比較當前和之前的目標提供了分析師不斷變化的預期的見解。</li>
</ul>
<p>為了獲得關於 Orchestra BioMed Hldgs 市場表現的有價值見解，請將這些分析師評估與關鍵財務指標結合考慮。保持信息靈通，利用我們的評級表做出明智的決策。</p>
<p>隨時瞭解 Orchestra BioMed Hldgs 的分析師評級。</p>
<p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
<h2>關於 Orchestra BioMed Hldgs 的所有信息</h2>
<p>Orchestra BioMed Holdings Inc 是一家生物醫學創新公司，通過風險回報共享合作伙伴關係加速高影響力技術的應用。其以合作為基礎的商業模式專注於與醫療器械公司建立戰略合作，以推動其開發產品的商業化。公司的旗艦產品候選包括用於治療高血壓的 BackBeat 心臟神經調節療法（CNT）和用於治療動脈粥樣硬化性動脈疾病的 Virtue Sirolimus AngioInfusionBalloon（SAB）。</p>
<h3>財務里程碑：Orchestra BioMed Hldgs 的歷程</h3>
<p><strong>市值分析：</strong> 公司的市值低於行業基準，相較於同行反映出較小的規模。這可能歸因於增長預期或運營能力等因素。</p>
<p><strong>收入挑戰：</strong> Orchestra BioMed Hldgs 在過去 3 個月的收入增長面臨困難。截至 2025 年 9 月 30 日，公司經歷了約 <strong>-12.77%</strong> 的下降。這表明其收入出現了下滑。與行業同行相比，公司在健康護理行業的增長率低於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> 公司的淨利潤率低於行業基準，顯示出在實現強勁盈利能力方面可能面臨困難。淨利潤率為 <strong>-2419.05%</strong>，公司可能需要解決有效成本控制方面的挑戰。</p>
<p><strong>股本回報率（ROE）：</strong> Orchestra BioMed Hldgs 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>-94.6%</strong>，公司可能在實現最佳財務回報方面面臨障礙。</p>
<p><strong>資產回報率（ROA）：</strong> Orchestra BioMed Hldgs 的 ROA 低於行業平均水平，表明在最大化資產回報方面可能面臨挑戰。ROA 為 <strong>-28.22%</strong>，公司可能在實現最佳財務表現方面面臨障礙。</p>
<p><strong>債務管理：</strong> Orchestra BioMed Hldgs 的債務與股本比率低於行業平均水平，為 <strong>0.37</strong>，反映出對債務融資的依賴較低，財務策略更為保守。</p>
<h2>理解分析師評級的相關性</h2>
<p>銀行和金融系統的專家，分析師專注於特定股票或定義行業的報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成被稱為股票分析師評級的內容。通常，分析師每季度評估和評級每隻股票一次。</p>
<p>分析師可能會通過對增長預估、收益和收入等指標的預測來補充他們的評級，為投資者提供更全面的展望。然而，投資者應注意，分析師和任何人一樣，可能會受到主觀觀點的影響，從而影響他們的預測。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

OBIO

<p>四位分析師最近對 Orchestra BioMed Hldgs（納斯達克代碼：OBIO）進行了評估，顯示出看漲和看跌情緒的混合。12 個月的平均目標價格為 14.5 美元，估計範圍從 11.00 美元到 20.00 美元。分析師評級包括 “增持” 和 “買入”，反映了基於市場狀況的調整。該公司面臨-12.77% 的收入下降和-2419.05% 的淨利潤率的挑戰。儘管其債務與股本比率為 0.37，屬於保守水平，但其財務表現指標如股本回報率（ROE）和資產回報率（ROA）低於行業平均水平，顯示出潛在的盈利能力問題</p>

<p>Across the recent three months, 4 analysts have shared their insights on Orchestra BioMed Hldgs (NASDAQ: OBIO), expressing a variety of opinions spanning from bullish to bearish.</p>
<div class="lb-trans"><p>在最近的三個月裏，4 位分析師對 Orchestra BioMed Hldgs（納斯達克：OBIO）分享了他們的見解，表達了從看漲到看跌的各種觀點。</p>
</div><p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的簡要概覽，展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Orchestra BioMed Hldgs, revealing an average target of $14.5, a high estimate of $20.00, and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 1.19% increase from the previous average price target of $14.33.</p>
<div class="lb-trans"><p>分析師為 Orchestra BioMed Hldgs 設定了 12 個月的價格目標，顯示出平均目標為 14.5 美元，最高預估為 20.00 美元，最低預估為 11.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的 14.33 美元的平均價格目標增加了 1.19%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767992438_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1767992438_0.png"/></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<div class="lb-trans"><h2>分析師評級調查：詳盡研究</h2>
</div><p>A comprehensive examination of how financial experts perceive Orchestra BioMed Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>對金融專家如何看待 Orchestra BioMed Hldgs 的全面審查源於最近的分析師行動。以下是關鍵分析師、他們最近的評估以及評級和價格目標調整的詳細總結。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>上調</td>
<td>超配</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>宣佈</td>
<td>買入</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>維持</td>
<td>買入</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>下調</td>
<td>超配</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Orchestra BioMed Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Orchestra BioMed Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Orchestra BioMed Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，反映了他們對 Orchestra BioMed Hldgs 近期發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析趨勢，分析師提供定性評估，從 “跑贏大盤” 到 “跑輸大盤”。這些評級傳達了對 Orchestra BioMed Hldgs 相對於更廣泛市場的相對錶現的預期。</li>
<li><strong>價格目標：</strong> 分析師在價格目標的調整中提供了對 Orchestra BioMed Hldgs 未來價值的估計。比較當前和之前的目標提供了分析師不斷變化的預期的見解。</li>
</ul>
</div><p>For valuable insights into Orchestra BioMed Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了獲得關於 Orchestra BioMed Hldgs 市場表現的有價值見解，請將這些分析師評估與關鍵財務指標結合考慮。保持信息靈通，利用我們的評級表做出明智的決策。</p>
</div><p>Stay up to date on Orchestra BioMed Hldgs analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Orchestra BioMed Hldgs 的分析師評級。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
</div><h2>All You Need to Know About Orchestra BioMed Hldgs</h2>
<div class="lb-trans"><h2>關於 Orchestra BioMed Hldgs 的所有信息</h2>
</div><p>Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings Inc 是一家生物醫學創新公司，通過風險回報共享合作伙伴關係加速高影響力技術的應用。其以合作為基礎的商業模式專注於與醫療器械公司建立戰略合作，以推動其開發產品的商業化。公司的旗艦產品候選包括用於治療高血壓的 BackBeat 心臟神經調節療法（CNT）和用於治療動脈粥樣硬化性動脈疾病的 Virtue Sirolimus AngioInfusionBalloon（SAB）。</p>
</div><h3>Financial Milestones: Orchestra BioMed Hldgs's Journey</h3>
<div class="lb-trans"><h3>財務里程碑：Orchestra BioMed Hldgs 的歷程</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低於行業基準，相較於同行反映出較小的規模。這可能歸因於增長預期或運營能力等因素。</p>
</div><p><strong>Revenue Challenges:</strong> Orchestra BioMed Hldgs's revenue growth over 3M faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately <strong>-12.77%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入挑戰：</strong> Orchestra BioMed Hldgs 在過去 3 個月的收入增長面臨困難。截至 2025 年 9 月 30 日，公司經歷了約 <strong>-12.77%</strong> 的下降。這表明其收入出現了下滑。與行業同行相比，公司在健康護理行業的增長率低於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-2419.05%,</strong> the company may need to address challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> 公司的淨利潤率低於行業基準，顯示出在實現強勁盈利能力方面可能面臨困難。淨利潤率為 <strong>-2419.05%</strong>，公司可能需要解決有效成本控制方面的挑戰。</p>
</div><p><strong>Return on Equity (ROE):</strong> Orchestra BioMed Hldgs's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-94.6%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Orchestra BioMed Hldgs 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>-94.6%</strong>，公司可能在實現最佳財務回報方面面臨障礙。</p>
</div><p><strong>Return on Assets (ROA):</strong> Orchestra BioMed Hldgs's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-28.22%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Orchestra BioMed Hldgs 的 ROA 低於行業平均水平，表明在最大化資產回報方面可能面臨挑戰。ROA 為 <strong>-28.22%</strong>，公司可能在實現最佳財務表現方面面臨障礙。</p>
</div><p><strong>Debt Management:</strong> Orchestra BioMed Hldgs's debt-to-equity ratio is below the industry average at <strong>0.37</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Orchestra BioMed Hldgs 的債務與股本比率低於行業平均水平，為 <strong>0.37</strong>，反映出對債務融資的依賴較低，財務策略更為保守。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析師評級的相關性</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>銀行和金融系統的專家，分析師專注於特定股票或定義行業的報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成被稱為股票分析師評級的內容。通常，分析師每季度評估和評級每隻股票一次。</p>
</div><p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<div class="lb-trans"><p>分析師可能會通過對增長預估、收益和收入等指標的預測來補充他們的評級，為投資者提供更全面的展望。然而，投資者應注意，分析師和任何人一樣，可能會受到主觀觀點的影響，從而影響他們的預測。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

評估 Orchestra BioMed Hldgs：4 位金融分析師的見解